Recurrence risk evaluation in T1N1M0/T2N0M0/T3N0M0 gastric cancer with TP53 codon 72 polyphorphism
Recurrence risk evaluation in T1N1M0/T2N0M0/T3N0M0 gastric cancer with TP53 codon 72 polyphorphism
复制标题
TP53密码子72多态性T1N1M0/T2N0M0/T3N0M0胃癌复发风险评估
DOI：
10.1002/jso.25718
复制
发表时间：
2019
期刊：
影响因子：
2.5
通讯作者：
Nishizuka SS
中科院分区：
文献类型：
--
作者：
Omori Y;Nomura T;Fukushima N;Takahashi F;Iwaya T;Koeda K;Nishizuka SS
背景T1 N1 M0/T2 N 0 M0/T3 N 0 M0胃癌术后辅助化疗不适用。然而，大约10%至30%的这些患者的经验复发和metastasis.MethodsAmong 658例胃癌患者接受胃切除术治疗的意图，130 T1 N1 M0/T2 N 0 M0和73 T3 N 0 M0患者参加。根据TP 53密码子72多态性Arg/Arg、Arg/Pro和Pro/Pro分析总生存期（OS）和无复发生存期（RFS）。通过TP 53密码子72多态性比较每个亚组的风险比（HR）。结果在189例多态性分析结果可用的患者中，5年和10年OS分别为84.9%和65.1%。5年和10年RFS分别为81.8%和65.4%。当研究队列根据多态性状态分为两组时（即“Arg/Arg和Arg/Pro”与Pro/Pro），操作系统都（HR，2.799; 95%置信区间[CI]，1.071 - 7.315;P= .036）和RFS（HR，2.639; 95% CI，1.025 - 6.794;在整个观察期内，Pro/Pro组的TP 53密码子72 Pro/Pro多态性可能会在T1 N1 M0/T2 N 0 M0/T3 N 0 M0胃癌中分离出相对高风险的患者群体。
BackgroundPostoperative adjuvant chemotherapy is not indicated for T1N1M0/T2N0M0/T3N0M0 gastric cancer. However, approximately 10% to 30% of these patients experience recurrence and metastasis.MethodsAmong 658 patients with gastric cancer who received gastrectomy with curative intent, 130 T1N1M0/T2N0M0 and 73 T3N0M0 patients were enrolled. Overall survival (OS) and relapse‐free survival (RFS) were analyzed based onTP53codon 72 polymorphisms Arg/Arg, Arg/Pro, and Pro/Pro. The hazard ratio (HR) for each subgroup was compared byTP53codon 72 polymorphisms.ResultsOf the 189 patients for whom polymorphism analysis results were available, the 5‐ and 10‐year OS was 84.9% and 65.1%, respectively. The 5‐ and 10‐year RFS was 81.8% and 65.4%, respectively. When the study cohort was divided into two groups according to polymorphism status (ie, “Arg/Arg and Arg/Pro” vs Pro/Pro), both the OS (HR, 2.799; 95% confidence interval [CI], 1.071‐7.315;P= .036) and RFS (HR, 2.639; 95% CI, 1.025‐6.794;P =.044) of the Pro/Pro group were significantly lower than those for the Arg/Arg and Arg/Pro groups across the entire observation period.ConclusionsTheTP53codon 72 Pro/Pro polymorphism may isolate a relatively high‐risk patient group in T1N1M0/T2N0M0/T3N0M0 gastric cancer.